Wedbush Has Lowered Expectations for Avalo Therapeutics (NASDAQ:AVTX) Stock Price

Avalo Therapeutics (NASDAQ:AVTX) had its target price reduced by stock analysts at Wedbush from $40.00 to $34.00 in a note issued to investors on Thursday, Marketbeat reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s target price indicates a potential upside of 91.66% from the company’s current price.

A number of other equities analysts have also recently commented on the company. Wall Street Zen raised Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. BTIG Research lifted their price target on Avalo Therapeutics from $40.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Wednesday, April 8th. Guggenheim initiated coverage on Avalo Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $50.00 price target on the stock. Finally, Citigroup reaffirmed an “outperform” rating on shares of Avalo Therapeutics in a research note on Wednesday, May 6th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Avalo Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $48.13.

Avalo Therapeutics Trading Down 6.7%

Shares of NASDAQ AVTX opened at $17.74 on Thursday. The stock has a market cap of $520.24 million, a price-to-earnings ratio of -3.25 and a beta of 0.78. Avalo Therapeutics has a 1-year low of $3.43 and a 1-year high of $24.27. The stock’s 50-day moving average is $15.83 and its 200 day moving average is $16.46.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. On average, analysts forecast that Avalo Therapeutics will post -3.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Mittie Doyle sold 3,970 shares of the business’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $18.01, for a total value of $71,499.70. Following the completion of the transaction, the insider owned 3,622 shares in the company, valued at $65,232.22. The trade was a 52.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 8,457 shares of the business’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $13.23, for a total value of $111,886.11. Following the completion of the transaction, the chief financial officer owned 423 shares of the company’s stock, valued at $5,596.29. This represents a 95.24% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 138,078 shares of company stock valued at $2,501,346. 4.46% of the stock is currently owned by corporate insiders.

Institutional Trading of Avalo Therapeutics

A number of hedge funds have recently bought and sold shares of the company. PFS Partners LLC increased its position in Avalo Therapeutics by 100.0% during the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after acquiring an additional 1,000 shares during the last quarter. BIT Capital GmbH purchased a new stake in Avalo Therapeutics during the third quarter valued at $25,000. Geode Capital Management LLC grew its holdings in Avalo Therapeutics by 2.5% during the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after purchasing an additional 2,648 shares during the period. Dimensional Fund Advisors LP bought a new stake in Avalo Therapeutics during the third quarter valued at about $143,000. Finally, Boothbay Fund Management LLC bought a new stake in Avalo Therapeutics during the second quarter valued at about $56,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Key Avalo Therapeutics News

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Mizuho raised its price target on Avalo Therapeutics to $45 from $39 and maintained an outperform rating, signaling continued optimism about the company’s longer-term potential. Avalo Therapeutics (NASDAQ:AVTX) Given New $45.00 Price Target at Mizuho
• Positive Sentiment: HC Wainwright reiterated a buy rating and set a $35 target, while Citizens JMP kept a market outperform stance with a $55 target, suggesting analysts still see substantial upside despite trimming estimates. Avalo Therapeutics (NASDAQ:AVTX) Price Target Lowered to $55.00 at Citizens Jmp Avalo Therapeutics (NASDAQ:AVTX) Price Target Lowered to $35.00 at HC Wainwright
• Neutral Sentiment: Several firms adjusted their valuation targets in both directions, including Wedbush cutting its target to $34 and Citizens JMP lowering its target to $55, which may be contributing to volatility but does not signal a bearish consensus. Avalo Therapeutics (NASDAQ:AVTX) Price Target Cut to $34.00 by Analysts at Wedbush
• Negative Sentiment: The company also urged investors to review Form 10-Q risk factors amid ongoing uncertainty, which is likely pressuring shares by reminding the market of regulatory and execution risks. Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.